MUNICH (Reuters) – Siemens AG (OTC:) is reviewing its majority stake in medical technology subsidiary Siemens (ETR:) Healthineers, the German technology group’s Chief Financial Officer Ralf Thomas told Handelsblatt newspaper.
The synergies with the maker of MRI machines and laboratory systems are not large enough to justify a capital commitment of 45 billion euros ($46.91 billion), Thomas told Handelsblatt, referring to how much Siemens’ 75% equity stake is worth .
“We evaluate the economic opportunities for Siemens AG in healthcare. We will deduce from this how instrumental Healthineers is as an investment. And then we will draw a conclusion from that,” he said, adding that the results will be presented. on a capital market day at the end of 2025.
Siemens AG spun off the Erlangen, Germany-based subsidiary in 2018 and took it public. Until now, Siemens had maintained that it would retain its majority stake in Siemens Healthineers.
However, Thomas recently raised the prospect of selling around 5% in the near future to finance the acquisition of US software company Altair.
Thomas said he remained committed to the Mobility train division, which investors have repeatedly called for to be spun off.
“The company is in good hands with us. I do not see that we should part with it at this time,” he told Handelsblatt.
($1 = 0.9592 euros)
